Clinical Trial Update: Cholesterol Lowering With EVOLocumab to Prevent Cardiac Allograft Vasculopathy in De-novo Heart Transplant Recipients [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating evolocumab to prevent cardiac allograft vasculopathy in de novo heart transplant recipients has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cardiac Allograft Vasculopathy

Drugs mentioned

• Evolocumab (evolocumab)

Snippet

Sponsor: Lars Gullestad | Conditions: Cardiac Allograft Vasculopathy | Phase 3 | Status: COMPLETED